A Basel, Switzerland and Boston, MA-based biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough genome-editing technology, into transformative medicines with the potential to cure serious human genetic diseases

Sectors
Healthcare
Life Sciences
First Invested
2015
Growth
Company Status
NASDAQ: CRSP
Board Members
Ali Behbahani, MD